Feasibility Study of a Smartphone Application for Detecting Skin Cancers in People With Albinism

Fidel Rubagumya, MD1,2; Sarah K. Nyagabona, MD3; Ahuka N. Longombe, MD4; Achille Manirakiza, MD1; John Ngowi, MD5; Theoneste Maniragaba, MD1; Doriane Sabushimike, MD6,7; Sandra Urusaro, BSN8; Diane A. Ndoli, MD5,9; Nazima Dharsee, MD5,9; Julius Mwaiselage, MD, PhD5; Daudi Mavura, MD6,7; Timothy P. Hanna, MD, MSc, PhD10,11; and Nazik Hammad, MD, MEHP10

PURPOSE Albinism affects some facets of the eye’s function and coloration, as well as hair and skin color. The prevalence of albinism is estimated to be one in 2,000-5,000 people in sub-Saharan Africa and one in 270 in Tanzania. People in Tanzania with albinism experience sociocultural and economic disparities. Because of stigma related to albinism, they present to hospitals with advanced disease, including skin cancers. Mobile health (mHealth) can help to bridge some of the gaps in detection and treatment of skin cancers affecting this population.

METHODS We assessed the feasibility of using a mobile application (app) for detection of skin cancers among people with albinism. The study was approved by the Ocean Road Cancer Institute institutional review board. Data, including pictures of the lesions, were collected using a mobile smartphone and submitted to expert reviewers. Expert reviewers’ diagnosis options were benign, malignant, or unevaluable.

RESULTS A total of 77 lesions from different body locations of 69 participants were captured by the NgoziYangu mobile app. Sixty-two lesions (81%) were considered malignant via the app and referred for biopsy and histologic diagnosis. Of those referred, 55 lesions (89%) were biopsied, and 47 lesions (85%) were confirmed as skin malignancies, whereas eight (15%) were benign.

CONCLUSION With an increasing Internet coverage in Africa, there is potential for smartphone apps to improve health care delivery channels. It is important that mobile apps like NgoziYangu be explored to reduce diagnostic delay and improve the accuracy of detection of skin cancer, especially in stigmatized groups.

JCO Global Oncol 6:1370-1375. © 2020 by American Society of Clinical Oncology

INTRODUCTION

The risk of developing skin malignancies in the African population with albinism is estimated to be 1,000-fold higher than in the general population, with skin squamous cell carcinoma of the head and neck region being the most prevalent malignancy.1-2 In Tanzania, persons living with albinism experience economic disparities and social marginalization throughout their lives. Given the lack of formal education, they tend to have low-paying jobs that expose them to the sun, with poor-to-nonexistent skin protection measures.3 In addition, when diagnosed with skin cancers, they often have poor access to health care.

Albinism is a genetic condition caused by a complete lack of, or reduction in, melanin production.4 There are two major types of albinism: ocular albinism, affecting some facets of the eye’s function and coloration, and the most common, oculocutaneous albinism (OCA), which also affects hair and skin color.4,5 The latter is autosomal recessive, with seven subtypes. The most common albinism disorder in Equatorial Africa is OCA, and of interest in our context is subtype 2 (OCA-2). OCA-2 results from a mutation of the OCA2 gene, which encodes the melanocyte-specific transporter protein.7

Although the number of detailed epidemiologic studies is limited, the prevalence of albinism is estimated to be one in 2,000-5,000 in sub-Saharan Africa.5 In Tanzania, the Tanzania Albinism Society (TAS) estimates that albinism likely affects one in 270 people or more than 150,000 individuals out of approximately 56 million nationally.5

To understand the natural history of skin cancer among people with albinism, in the 1980s, a cohort of people with albinism were enrolled in a study in Tanzania and followed from birth. They were found to have distinct skin changes during their first year of life, and two decades later, they were reported to develop considerable malignant changes with associated mortality in some cases.10 In an effort to curb late-stage
presentations of skin cancers among people with albinism, this study and others made several recommendations for skin cancer prevention, ranging from community destigmatization and patient education to effective genetic counseling.\textsuperscript{11}

Health-care-system– and patient-related delays have been reported for skin malignancy conditions, and variations exist, depending on the population’s level of awareness.\textsuperscript{12} Across low- and middle-income countries, access to cancer care is limited, and patient delays often reflect a lack of awareness, difficulties in access, and limited availability of health and diagnostic facilities.\textsuperscript{13,14} Even when care is available, patients, particularly those with albinism, often do not seek care because of stigma, which further delays or prevents diagnosis and treatment.\textsuperscript{15}

Mobile health (mHealth), or the practice of medicine and public health supported by mobile devices, can help to bridge some of the gaps in both detection and treatment.\textsuperscript{16} One report estimates that mobile telecommunication technology use has reached nearly 46% in sub-Saharan Africa.\textsuperscript{17} Mobile phone applications (apps) assessing skin lesions in the general population, especially in high-income countries, have been used with various levels of success.\textsuperscript{18-20} Store-and-forward teledermatology has been reported to decrease delays in management of skin cancers, reduce referrals to a dermatologist, and limit treatment abandonment or loss to follow-up.\textsuperscript{21} However, little is known about such mHealth tools for skin cancer in low-income countries, particularly in people with albinism in Africa. Hence, the purpose of this study was to explore the feasibility of using a mobile app for detection of skin cancers in people with albinism in Tanzania.

**METHODS**

This was a prospective study aimed at assessing the feasibility of using a mobile app for detection of skin cancers among people with albinism presenting with skin lesions in Dar es Salaam, Tanzania.

**The Mobile App and Data Entry**

The mobile app, NgoziYangu (a Swahili word that means my skin), has functions to acquire images either directly through the mobile camera or by uploading an image that had already been taken and stored. It also allowed our research assistant to add patient information (eg, sex, contacts, date of birth, and so on) and skin lesion characteristics. The mobile device used for image acquisition was an Android smartphone with a 13-megapixel autofocus camera (1080 p and 30 fps per second in video mode).

Using the web app, our research assistant was able to enter the patients’ information and also upload images taken and stored earlier. The main purpose of the web app was for expert reviewers (an oncologist, a dermatologist, and a pathologist) to use their personal computers to view de-identified images and brief clinical information, and provide advice on management.

**Outcomes**

We evaluated the proportion of patients flagged by the NgoziYangu app who were histologically confirmed to have cancer. Sensitivity, specificity, accuracy, and positive predictive value could not be directly measured because premalignant lesions and those deemed to be benign were not biopsied due to lack of funds.

**Data Collection**

This study was approved by the Ocean Road Cancer Institute (ORCI) institutional review board. To participate in the study, patients received explanations about the study and signed informed consents. In conjunction with this study, ORCI started a screening program for people with albinism. The TAS made calls to its members with skin lesions inviting them to attend these clinics. The clinicians...
in these clinics were different from those evaluating the images remotely but were aware of our study. Our research assistant attended these clinics and collected data from patients who were screened. As illustrated in Figure 1, during these clinics, participants’ identification information (age, place of residence, occupation, and so on), lesion characteristics (site, duration of the lesion, number of lesions), and the image of the lesion were all captured. All the captured information and images were de-identified, securely stored on a cloud drive, and accessed by the expert reviewers. Expert reviewers’ diagnosis options were benign, malignant, or unevaluable (which required a picture to be retaken). Lesions deemed to be nonmalignant by two or all three reviewers were scheduled to be followed up every 3 months by TAS because the duration of the study was short and funds were limited. Patients with lesions deemed suggestive of malignancy by at least two of the three reviewers were referred for biopsies, and samples were sent for histologic review and reporting. Patients with pathologically confirmed biopsies were advised by the clinical team to receive additional treatment at ORCI. As a stakeholder in this study, TAS was charged with offering patient navigation services until the last disposition.

Analytic Plan
The statistical analyses were performed with IBM SPSS Statistics version 22.0 (IBM, Armonk, NY). Because biopsies were not obtained from premalignant lesions or lesions clinically diagnosed as benign, test accuracy could not be determined. However, we performed a sensitivity analysis using available data to determine a range of possible accuracy, sensitivity, and specificity for the app using MedCalc. For this sensitivity analysis, we considered scenarios in which all benign and premalignant lesions were either (1) all pathologically proven malignancies or (2) all nonmalignant. We also considered a median scenario in which (3) half of all unbiopsied patients were malignant.

RESULTS
The statistical analysis included all patients who were seen in the clinic for people with albinism at ORCI during the study period. A total of 77 lesions from different body locations in 69 participants were captured by the NgoziYangu mobile app (Table 1). The youngest patient with a skin lesion was 22 years of age, and the oldest was 67 years (median, 45 years), with a mean age of 47 years (standard

| TABLE 1. Disease Characteristics |
|----------------------------------|
| Characteristic                   | No. | %  |
| No. of lesions captured by NgoziYangu app | 77   | 100 |
| No. of lesions considered malignant or premalignant via the app | 62   | 81  |
| No. of lesions biopsied based on suspicion of malignancy | 55   | 71  |
| No. of pathology-confirmed malignant lesions among lesions considered malignant or premalignant via the app | 47   | 76  |
| Tumor/lesion location (both malignant and benign) |      |    |
| Head and neck                    | 52   | 68  |
| Trunk                            | 4    | 5   |
| Upper limbs                      | 14   | 18  |
| Lower limbs                      | 7    | 9   |
| Histologically confirmed patients (n = 55) |      |    |
| Malignant (n = 47)               |      |    |
| Squamous cell carcinoma          | 31   | 56  |
| Basal cell carcinoma             | 11   | 20  |
| Mixed                            | 5    | 9   |
| Benign (n = 8)                   | 8    | 15  |

Abbreviation: app, application.
deviation ± 10.98 years); 43 patients (62%) were males. The expert reviewers (a dermatologist, an oncologist, and a pathologist) considered 62 lesions (81%) to be malignant; therefore, patients with these lesions were referred for biopsy and histologic diagnosis (gold standard). Fifteen of 77 lesions (19%) were considered benign via the app. Five lesions were considered unevaluable by the reviewers, the photos were retaken, and they were counted among the 77. Of those referred, seven lesions (11%) were considered premalignant/benign and treated as such with cryotherapy, curettage, and/or ointments (imiquimod cream), whereas 55 lesions (89%) were biopsied. Among those biopsied, 47 lesions (85%) were confirmed as skin malignancies, whereas the remaining eight (15%) were benign. Among the patients with malignant disease, 31 (56%) had squamous cell carcinoma, 11 of whom (20%) had basal cell carcinoma and five (9%) had mixed type. Among the benign lesions, the most common diagnoses were actinic keratos, acanthosis, solar elastosis, and orthokeratosis.

**DISCUSSION**

Tanzania is believed to be one of the African countries with a high number of people with albinism. People with albinism in Tanzania and sub-Saharan Africa in general are faced with several health inequities and disparities. This vulnerable group is often subject to stigmatization and brutal attacks, including mutilation, violence, and death. They also are prone to various types of skin lesions and skin cancers. Most are peasant farmers and others have low-paying jobs with no proper source of income to facilitate their transport to seek and pay for medical care. Most present with late stages of skin cancer. Persistent stigmatization, discrimination, and persecution compound poor access to health care, resulting in poor health outcomes.

With the scarcity of dermatologic services and trained dermatologists in Tanzania, innovative approaches involving the use of mobile apps could decrease the number of people with albinism whose skin lesions would otherwise be left unattended, consequently with delayed cancer diagnosis.

To our knowledge, the NgoziYangu app was the first teledermatology mobile app in Tanzania and the first in sub-Saharan Africa used for early detection of skin cancers in a population of people with albinism. Additionally, most dermato-oncology mobile apps were designed for melanoma, whereas the NgoziYangu app targeted all potentially malignant skin lesions affecting people with albinism. In contrast to other mobile apps that use automated analysis, which has a high likelihood of giving false-negative results, the NgoziYangu app uses a store-and-forward image-based system, which has been shown to have better accuracy. In this study, 76% of lesions considered malignant or premalignant via the app were pathologically proven to be cancer. Automated image analysis by a smartphone algorithm for melanoma has reported 80% accuracy to detect cancer. Although the accuracy of NgoziYangu could not be determined because of the limitations of this study, our sensitivity analysis suggests the accuracy of the app is likely to be favorable.

Despite its large size and population, Tanzania has an Internet penetration rate of 46% and has witnessed an increasing uptake of mobile technology by the poor or remote populations. The use of mHealth will be the most convenient, fastest, and cost-effective way to connect specialized care that would otherwise be unreachable to vulnerable groups like people living with albinism.

Our study suggests that combined with other enabling factors, including the assistance of the TAS, a coordinated care plan, and availability of the Internet, people with albinism presenting with skin lesions could possibly undergo an initial evaluation remotely using mobile apps embedded in smartphones. Patients with lesions suggestive of malignancy can be carefully linked to the point of care without unnecessary referral. Given the low number of people with albinism attending the ORCI clinic, we expect that such an approach could have a major impact on minimizing diagnostic delay and ensuring presentation to health providers. Challenges include the distance from Dar es Salaam to Kilimanjaro Medical Center, which is located in the Moshi region (338 miles away). This can be mitigated by equipping regional referral hospitals to take care of basic needs, including biopsy.

This study also demonstrated the feasibility of collaboration between academic centers and advocacy organizations, such as the TAS. This partnership allowed delivery of care and research that hopefully will help decrease the equity gap experienced by people living with Albinism.

Although the use of smartphone apps in health care offers hope for improved quality of care, it also raises several ethical and legal concerns, such as data security and confidentiality. Teledermatology needs to be supplemented with other clinical information, because in many instances, photographs alone are not enough. Notably, in our care process, a clinician evaluated the skin lesion in person, and benign lesions were treated without biopsy. Mobile apps should not replace standard health care providers’ consultations because diagnostic inaccuracy is possible.

Limitations of this study included not being able to biopsy lesions that were deemed to be benign by the NgoziYangu app. This could have helped test the accuracy of the app. However, we performed a sensitivity analysis that suggested that the app is likely to have reasonable accuracy and sensitivity. Field testing of the app between ORCI and remote sites is also required. The acceptability of the technology in the community of people with albinism and the impact on mitigating diagnostic delay also need to be determined.
Technologies that harness the increasing Internet coverage in Africa such as NgoziYangu have the potential to enhance access to care and decrease disparities for people with albinism by linking vulnerable patients with health care professionals. Our study has demonstrated that use of such technology is feasible and worthy of additional investigation. Future studies should ascertain the safety, accuracy, acceptability, and impact on health outcomes of such mobile apps, particularly in people with albinism.

**AFFILIATIONS**

1Department of Oncology, Rwanda Military Hospital, Kigali, Rwanda
2University of Global Health Equity, Burera, Rwanda
3Department of Epidemiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
4Polyclinique du Millénaire de Kisangani, Kisangani, Democratic Republic of Congo
5Department of Oncology, Ocean Road Cancer Institute, Dar es Salaam, Tanzania
6Department of Dermatology, Regional Dermatology Training Center, Moshi, Tanzania
7Kilimanjaro Christian Medical Center, Moshi, Tanzania
8Inshuti Mubuzima, Kigali, Rwanda
9Department of Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
10Division of Cancer Care and Epidemiology, Cancer Research Institute at Queen’s University, Kingston, Canada
11Department of Oncology, Queen’s University, Kingston, Ontario, Canada

**CORRESPONDING AUTHOR**

Fidel Rubagumya, MD, Rwanda Military Hospital, KK739ST Kanombe, Kicukiro District, Kigali City, PO Box 3377, Kigali, Rwanda; Twitter: @Rubagumyaf; e-mail: fidel.rubagumya@yahoo.com.

**SUPPORT**

Supported by International Innovation Grant No. 12665 of Conquer Cancer, the ASCO Foundation.

**AUTHOR CONTRIBUTIONS**

Conception and design: Fidel Rubagumya, Sarah K. Nyagabona, Achille Manirakiza, Theoneste Maniragaba, Nazima Dharsee, Julius Mwaiselage, Daudi Savura, Timothy P. Hanna, Nazik Hammad

Administrative support: Sarah K. Nyagabona, Ahuka N. Longombe, Theoneste Maniragaba, Nazima Dharsee, Julius Mwaiselage, Timothy P. Hanna

Provision of study materials or patients: Sarah K. Nyagabona, John Ngowi, Theoneste Maniragaba, Julius Mwaiselage, Daudi Savura

Collection and assembly of data: Fidel Rubagumya, Sarah K. Nyagabona, Ahuka N. Longombe, Achille Manirakiza, John Ngowi, Theoneste Maniragaba, Doriane Sabushikime, Julius Mwaiselage, Timothy P. Hanna

Data analysis and interpretation: Fidel Rubagumya, Sarah K. Nyagabona, Theoneste Maniragaba, Sandra Ursaro, Diane A. Ndoli, Nazima Dharsee, Julius Mwaiselage, Timothy P. Hanna, Nazik Hammad

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/site/misc/authors.html.

Sandra Ursaro
Other Relationship: Partners in Health

Nazima Dharsee
Research Funding: Pfizer Oncology (Inst)

Timothy P. Hanna
Research Funding: Roche

No other potential conflicts of interest were reported.

**ACKNOWLEDGMENT**

We extend our gratitude to the Tanzania Albinism Society for their tremendous support in sensitizing individuals with albinism to come for skin cancer screening at Ocean Road Cancer Institute. We also thank our patients for consenting to participate in this study and ASCO for their support through the International Innovation Grant. T.P.H. holds a research chair provided by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario (#IA-035).

**TABLE 2. Estimation of Test Performance Characteristics Based on Assumptions Regarding Unbiopsied Lesions Considered Clinically to Be Benign or Premalignant**

| Scenario                                                                 | Sensitivity (95% CI) | Specificity (95% CI) | Prevalence (95% CI) | Accuracy (95% CI) |
|-------------------------------------------------------------------------|----------------------|----------------------|---------------------|-------------------|
| Assuming all clinically diagnosed benign or premalignant lesions were true malignancies | 68 (56 to 79)        | 0 (0 to 37)          | 90 (81 to 95)       | 61 (49 to 72)     |
| Assuming all clinically diagnosed benign or premalignant lesions were not malignant | 100 (92 to 100)      | 73 (54 to 88)        | 61 (49 to 72)       | 90 (81 to 95)     |
| Assuming half of all clinically diagnosed benign or premalignant lesions were true malignancies | 81 (69 to 90)        | 58 (34 to 80)        | 75 (64 to 84)       | 75 (64 to 84)     |

© 2020 by American Society of Clinical Oncology
REFERENCES

1. Iverson U, Iverson OH: Tumours of the skin, in Templeton AC (ed) Tumours in a Tropical Country: A Survey of Uganda, 1964-68. Springer Verlag, New York, NY, 1973, pp 180-199.

2. Okoro AN: Albinism in Nigeria. A clinical and social study. Br J Dermatol 92:485-492, 1975.

3. Brocco G: Labeling albinism: Language and social surrounding people with albinism in Tanzania. Disabil Soc 30:1143-1157, 2015.

4. Tuli AM, Valenzuela RK, Kamugisha E, et al: Albinism and disease causing pathogens in Tanzania: Are alleles that are associated with OCA2 being maintained by balancing selection? Med Hypotheses 79:875-878, 2012.

5. Spritz RA, Fukai K, Holmes SA, et al: Frequent intragenic deletion of the P gene in Tanzanian patients with type II oculocutaneous albinism (OCA2). Am J Hum Genet 56:1320-1323, 1995.

6. Grønskov K, Ek J, Brondum-Nielsen K: Oculocutaneous albinism. Orphanet J Rare Dis 2:43, 2007.

7. NCBI: OCA2 melanosomal transmembrane protein [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=4948.

8. Franklin A, Lund P, Bradbury-Jones C, et al: Children with albinism in African regions: Their rights to “being” and “doing.” BMC Int Health Hum Rights 18:2, 2018.

9. Lapidos J: How many albinos are there in Tanzania? https://slate.com/news-and-politics/2009/01/how-many-albinos-are-there-in-tanzania.html

10. Luande J, Henschke CI, Mohammed N: The Tanzanian human albinoid skin. Natural history. Cancer 55:1823-1828, 1985.

11. Alexander GA, Henschke UK: Advanced skin cancer in Tanzanian albinos: Preliminary observations. J Natl Med Assoc 73:1047-1054, 1981.

12. Temoshok L, DiClemente RJ, Sweet DM, et al: Factors related to patient delay in seeking medical attention for cutaneous malignant melanoma. Cancer 54:3048-3053, 1984.

13. Lövgren J, Lesvišáhi T, Tishelman C, et al: Time spans from first symptom to treatment in patients with lung cancer - The influence of symptoms and demographic characteristics. Acta Oncol 47:397-405, 2008.

14. Richard MA: Delays in diagnosis and melanoma prognosis (?): The role of patients. Int J Cancer 89:271-279, 2000.

15. Brocco G: Albinism, stigma, subjectivity and global-local discourses in Tanzania. Anthropol Med 23:229-243, 2016.

16. Steinhubl SR, Muse ED, Topol EJ: The emerging field of mobile health. Sci Transl Med 7: 283rv3, 2015.

17. World Bank Group: Digital dividends overview. http://documents.worldbank.org/curated/en/961621467994698644/pdf/102724-WDR-WDR2016Overview-ENGLISH-WebResBox-394840B-OUO-9.pdf.

18. Wolf JA, Moreau J-F, Akilov O, et al: Diagnostic inaccuracy of smartphone applications for melanoma detection. JAMA Dermatol 149:422-426, 2013.

19. Kassianos AP, Emery JD, Murchie P, et al: Smartphone applications for melanoma detection by community, patient and generalist clinician users: A review. Br J Dermatol 172:1507-1518, 2015.

20. Maier T, Kulichova D, Schotten K, et al: Accuracy of a smartphone application using fractal image analysis of pigmented moles compared to clinical diagnosis and histological result. J Eur Acad Dermatol Venereol 29:663-667, 2015.

21. Rat C, Hild S, Rault Sérandour J, et al: Use of smartphones for early detection of melanoma: Systematic review. J Med Internet Res 20:e135, 2018.

22. Malone A: The albino tribe butchered to feed a gruesome trade in ‘magical’ body parts. https://www.dailymail.co.uk/news/article-1215949/The-albino-tribe-butchered-feed-gruesome-trade-magical-body-parts.html.

23. Hong ES, Zeeb H, Repacholi MH: Albinism in Africa as a public health issue. http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-6-212.

24. Under the Same Sun: Reported attacks of persons with albinism – most recent attacks included. http://www.underthesamesun.com/sites/default/files/Attacks%20of%20PWA%20-%20extended%20version.pdf.

25. Nakkazi E: People with albinism in Africa: Contending with skin cancer. Lancet 394:553-554, 2019.

26. Cruz-Inigo AE, Ladzinski B, Sethi A: Albinism in Africa: Stigma, slaughter and awareness campaigns. Dermatol Clin 29:79-87, 2011.

27. Mabula JB, Chalya PL, Mchembe MD, et al: Skin cancers among Albinos at a university teaching hospital in Northwestern Tanzania: A retrospective review of 64 cases. BMC Dermatol 12:5, 2012.

28. Janda M, Loescher LJ, Banan P: Lesion selection by melanoma high-risk consumers during skin self-examination using mobile teledermoscopy. JAMA Dermatol 150:656-658, 2014.

29. Statista: Voice telecom and internet penetration in Tanzania 2013-2019. https://www.statista.com/statistics/1082352/tanzania-voice-telecom-and-internet-penetration/.

30. Denecke K, Barnidt P, Bond C, et al: Ethical issues of social media usage in healthcare. Yearb Med Inform 10:137-147, 2015.

31. Thissen M, Udrea A, Hacking M, et al: mHealth app for risk assessment of pigmented and nonpigmented skin lesions - A study on sensitivity and specificity in detecting malignancy. Telemed J E Health 23:948-954.